Therapeutic Drug Monitoring and Clinical Outcomes in Immune Mediated Diseases
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Therapeutic Drug Monitoring and Clinical Outcomes in Immune Mediated Diseases
Authors
Keywords
-
Journal
INFLAMMATORY BOWEL DISEASES
Volume 22, Issue 10, Pages 2527-2537
Publisher
Oxford University Press (OUP)
Online
2016-08-31
DOI
10.1097/mib.0000000000000867
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases
- (2016) Bella Ungar et al. Clinical Gastroenterology and Hepatology
- Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis
- (2016) Johannan F. Brandse et al. Clinical Gastroenterology and Hepatology
- Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis
- (2016) Konstantinos Papamichael et al. Clinical Gastroenterology and Hepatology
- Higher Adalimumab Levels Are Associated with Histologic and Endoscopic Remission in Patients with Crohnʼs Disease and Ulcerative Colitis
- (2016) Andres J. Yarur et al. INFLAMMATORY BOWEL DISEASES
- Systematic Review and Meta-Analysis: Serum Infliximab Levels During Maintenance Therapy and Outcomes in Inflammatory Bowel Disease
- (2016) Clare Moore et al. Journal of Crohns & Colitis
- Undetectable anti-TNF drug levels in patients with long-term remission predict successful drug withdrawal
- (2015) S. Ben-Horin et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Detection of Small Bowel Mucosal Healing and Deep Remission in Patients With Known Small Bowel Crohn’s Disease Using Biomarkers, Capsule Endoscopy and Imaging
- (2015) Uri Kopylov et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Optimizing biologic treatment in IBD: objective measures, but when, how and how often?
- (2015) Shomron Ben-Horin et al. BMC GASTROENTEROLOGY
- Long-Term Outcome of Patients With Crohn’s Disease Who Discontinued Infliximab Therapy Upon Clinical Remission
- (2015) Konstantinos Papamichael et al. Clinical Gastroenterology and Hepatology
- Levels of Drug and Antidrug Antibodies Are Associated With Outcome of Interventions After Loss of Response to Infliximab or Adalimumab
- (2015) Henit Yanai et al. Clinical Gastroenterology and Hepatology
- Withdrawal of Immunomodulators After Co-treatment Does Not Reduce Trough Level of Infliximab in Patients With Crohn’s Disease
- (2015) David Drobne et al. Clinical Gastroenterology and Hepatology
- Individualized Therapy Is a Long-Term Cost-Effective Method Compared to Dose Intensification in Crohn’s Disease Patients Failing Infliximab
- (2015) Casper Steenholdt et al. DIGESTIVE DISEASES AND SCIENCES
- Preemptive Dose Optimization Using Therapeutic Drug Monitoring for Biologic Therapy of Crohn’s Disease: Avoiding Failure While Lowering Costs?
- (2015) Niels Vande Casteele et al. DIGESTIVE DISEASES AND SCIENCES
- Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting
- (2015) Andrea Warman et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Tu1304 Faecal Calprotectin Measurement and Infliximab Trough Levels Predict Therapeutic Evolution CD Patients in Clinical Remission
- (2015) Xavier Roblin et al. GASTROENTEROLOGY
- 286 Drug Concentrations and Antibodies to Infliximab Are Inferior to the Impact of Disease Burden in Primary Non-Response to Infliximab in Crohn's Disease Patients
- (2015) Thomas Billiet et al. GASTROENTEROLOGY
- Su1094 A Systematic Review and Meta-Analysis of Non-Invasive Biomarkers for Assessing Disease Activity in Inflammatory Bowel Disease
- (2015) Mahmoud H. Mosli et al. GASTROENTEROLOGY
- Tu1291 Infliximab Serum Levels Do Not Predict Remission After the Induction Phase in Crohn's Disease Patients
- (2015) Maria Chaparro et al. GASTROENTEROLOGY
- Tu1236 Infliximab Trough Level Thresholds Vary Depending on the Efficacy Criterion Chosen in IBD Patients
- (2015) Xavier Roblin et al. GASTROENTEROLOGY
- Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
- (2015) Niels Vande Casteele et al. GASTROENTEROLOGY
- Proteolytic Cleavage and Loss of Function of Biologic Agents That Neutralize Tumor Necrosis Factor in the Mucosa of Patients With Inflammatory Bowel Disease
- (2015) Paolo Biancheri et al. GASTROENTEROLOGY
- Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial
- (2015) Filip Baert et al. GUT
- Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up
- (2015) Robert V Bryant et al. GUT
- The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study
- (2015) Andres J Yarur et al. GUT
- Blood-based Biomarkers Used to Predict Disease Activity in Crohnʼs Disease and Ulcerative Colitis
- (2015) Robert Burakoff et al. INFLAMMATORY BOWEL DISEASES
- Using Corticosteroids to Reshape the Gut Microbiome
- (2015) Edmond Y. Huang et al. INFLAMMATORY BOWEL DISEASES
- Role for Therapeutic Drug Monitoring During Induction Therapy with TNF Antagonists in IBD
- (2015) Konstantinos Papamichael et al. INFLAMMATORY BOWEL DISEASES
- Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: Adding value to current practice
- (2015) Niels Vande Casteele et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Serum Concentration of Anti-TNF Antibodies, Adverse Effects and Quality of Life in Patients with Inflammatory Bowel Disease in Remission on Maintenance Treatment
- (2015) Johannan F. Brandse et al. Journal of Crohns & Colitis
- Endoscopic Factors Influencing Fecal Calprotectin Value in Crohn’s Disease
- (2015) F. Goutorbe et al. Journal of Crohns & Colitis
- Biologic agents for IBD: practical insights
- (2015) Silvio Danese et al. Nature Reviews Gastroenterology & Hepatology
- Low Dose Infliximab for Prevention of Postoperative Recurrence of Crohn’s Disease: Long Term Follow-Up and Impact of Infliximab Trough Levels and Antibodies to Infliximab
- (2015) Dario Sorrentino et al. PLoS One
- Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practice
- (2015) Thierry Schaeverbeke et al. RHEUMATOLOGY
- Significance of low level infliximab in the absence of anti-infliximab antibodies
- (2015) Bella Ungar WORLD JOURNAL OF GASTROENTEROLOGY
- Anti-TNF levels and anti-drug antibodies, immunosuppressants and clinical outcomes in inflammatory bowel disease
- (2015) Christina Ha et al. Expert Review of Gastroenterology & Hepatology
- 566 Infliximab Concentration and Clinical Outcome in Patients With Ulcerative Colitis
- (2015) Walter Reinisch et al. GASTROENTEROLOGY
- A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease
- (2014) B. G. Levesque et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Clinical Implications of Measuring Drug and Anti-Drug Antibodies by Different Assays When Optimizing Infliximab Treatment Failure in Crohn's Disease: Post Hoc Analysis of a Randomized Controlled Trial
- (2014) Casper Steenholdt et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Mesalamine Dose Escalation Reduces Fecal Calprotectin in Patients With Quiescent Ulcerative Colitis
- (2014) Mark T. Osterman et al. Clinical Gastroenterology and Hepatology
- Pharmacokinetics in IBD: Ready for Prime Time?
- (2014) Xavier Roblin et al. CURRENT DRUG TARGETS
- Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial
- (2014) Freddy Cornillie et al. GUT
- The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
- (2014) Niels Vande Casteele et al. GUT
- Proactive Therapeutic Concentration Monitoring of Infliximab May Improve Outcomes for Patients with Inflammatory Bowel Disease
- (2014) Byron P. Vaughn et al. INFLAMMATORY BOWEL DISEASES
- Trough s-infliximab and antibodies towards infliximab in a cohort of 79 IBD patients with maintenance infliximab treatment
- (2014) Per Marits et al. Journal of Crohns & Colitis
- Tailoring anti-TNF therapy in IBD: drug levels and disease activity
- (2014) Shomron Ben-Horin et al. Nature Reviews Gastroenterology & Hepatology
- Therapeutic drug monitoring in patients with inflammatory bowel disease
- (2014) Andres J Yarur WORLD JOURNAL OF GASTROENTEROLOGY
- Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease
- (2013) R. Khanna et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient
- (2013) Niels Vande Casteele et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies
- (2013) Sandra Garcês et al. ANNALS OF THE RHEUMATIC DISEASES
- A Test-based Strategy Is More Cost Effective Than Empiric Dose Escalation for Patients With Crohn's Disease Who Lose Responsiveness to Infliximab
- (2013) Fernando S. Velayos et al. Clinical Gastroenterology and Hepatology
- Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease
- (2013) Jean–Frédéric Colombel et al. Clinical Gastroenterology and Hepatology
- Association Between Pharmacokinetics of Adalimumab and Mucosal Healing in Patients With Inflammatory Bowel Diseases
- (2013) Xavier Roblin et al. Clinical Gastroenterology and Hepatology
- Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis
- (2013) William J. Sandborn et al. GASTROENTEROLOGY
- Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial
- (2013) Casper Steenholdt et al. GUT
- The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab
- (2013) Bella Ungar et al. GUT
- Therapeutic Drug Monitoring of Infliximab and Mucosal Healing in Inflammatory Bowel Disease
- (2013) Stephane Paul et al. INFLAMMATORY BOWEL DISEASES
- Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn’s disease under scheduled maintenance treatment
- (2013) Hirotsugu Imaeda et al. JOURNAL OF GASTROENTEROLOGY
- Immunogenicity of Monoclonal Antibodies Against Tumor Necrosis Factor Used in Chronic Immune-Mediated Inflammatory Conditions
- (2013) Jose Ramon Maneiro et al. JAMA Internal Medicine
- Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis
- (2012) Kavinderjit S Nanda et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study
- (2012) Aatke van der Maas et al. BMC MUSCULOSKELETAL DISORDERS
- Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Inflammatory Bowel Disease
- (2012) Ingrid Ordás et al. Clinical Gastroenterology and Hepatology
- Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms
- (2012) I Ordás et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Factors affecting outcomes in Crohn's disease over 15 years
- (2012) Jacques Cosnes et al. GUT
- Should anti-TNF-α drug levels and/or anti-drug antibodies be assayed in patients treated for rheumatoid arthritis?
- (2012) Denis Mulleman et al. JOINT BONE SPINE
- P334 Concentration effect relationship of infliximab in Crohn's disease: Results of a cohort study
- (2012) C. Lamblin et al. Journal of Crohns & Colitis
- Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease
- (2012) Martin Bortlik et al. Journal of Crohns & Colitis
- Review article: causative factors and the clinical management of patients with Crohn’s disease who lose response to anti-TNF-α therapy
- (2011) S. Danese et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Differences in phenotype and disease course in adult and paediatric inflammatory bowel disease - a population-based study
- (2011) C. Jakobsen et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis
- (2011) T. Takeuchi et al. ANNALS OF THE RHEUMATIC DISEASES
- Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped
- (2011) Edouard Louis et al. GASTROENTEROLOGY
- Trough Levels and Antibodies to Infliximab May Not Predict Response to Intensification of Infliximab Therapy in Patients With Inflammatory Bowel Disease
- (2011) Benjamin Pariente et al. INFLAMMATORY BOWEL DISEASES
- Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up
- (2011) Geertje M. Bartelds JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis
- (2011) D. Pascual-Salcedo et al. RHEUMATOLOGY
- The efficacy of shortening the dosing interval to once every six weeks in Crohn’s patients losing response to maintenance dose of infliximab
- (2010) U. Kopylov et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
- (2010) Waqqas Afif et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Low-Dose Maintenance Therapy With Infliximab Prevents Postsurgical Recurrence of Crohn's Disease
- (2010) Dario Sorrentino et al. Clinical Gastroenterology and Hepatology
- Monitoring functional serum antitumor necrosis factor antibody level in Crohnʼs disease patients who maintained and those who lost response to anti-TNF
- (2010) Akihiro Yamada et al. INFLAMMATORY BOWEL DISEASES
- Influence of anti-infliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patients
- (2010) Axel Finckh et al. JOINT BONE SPINE
- Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
- (2010) Jean Frédéric Colombel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab
- (2009) C. MA et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review
- (2009) Javier P Gisbert et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry
- (2009) Merete Lund Hetland et al. ARTHRITIS AND RHEUMATISM
- Biologic Therapy for Rheumatoid Arthritis
- (2009) Laura J. Gibbons et al. BIODRUGS
- Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease
- (2009) Konstantinos Karmiris et al. GASTROENTEROLOGY
- Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis
- (2009) C H Seow et al. GUT
- Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis
- (2008) T R D J Radstake et al. ANNALS OF THE RHEUMATIC DISEASES
- Withdrawal of Immunosuppression in Crohn's Disease Treated With Scheduled Infliximab Maintenance: A Randomized Trial
- (2008) Gert Van Assche et al. GASTROENTEROLOGY
- Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study)
- (2008) Inger Camilla Solberg et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor expression in the synovium
- (2007) C A Wijbrandts et al. ANNALS OF THE RHEUMATIC DISEASES
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now